Cargando…

PB2228: PRECISION MEDICINE IN THALASSEMIA: 30-YEAR EXPERIENCE AT SINGLE INSTITUTE FROM SAUDI ARABIA

Detalles Bibliográficos
Autor principal:	Al Jaouni, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431717/ http://dx.doi.org/10.1097/01.HS9.0000851740.34465.4e

Ejemplares similares

PB2228: WHAT IS THE UTILITY OF THE MYSEC-PM ON SECONDARY MYELOFIBROSIS RISK STRATIFICATION IN A REAL LIFE SETTING?
por: Moura, Pedro, et al.
Publicado: (2023)

PB2542: MOLECULAR SPECTRUM OF ALPHA THALASSEMIA MUTATIONS IN THE WESTERN PROVINCE OF SAUDI ARABIA AND RECOMMENDATION FOR PREMARITAL SCREENING
por: Attallah, Samy, et al.
Publicado: (2023)

PB2520: NEWBORN SCREENING PROGRAM IN SAUDI ARABIA FOR EARLY DETECTION OF HEMOGLOBINOPATHIES AND G6PD
por: Ezzat, Hatoon, et al.
Publicado: (2023)

PB2220: MORTALITY IN PATIENTS WITH HEMOGLOBINOPATHIES AND (SARS-COV-2) COVID-19 INFECTION: SAUDI ARABIA EXPERIENCE
por: Ezzat, H., et al.
Publicado: (2022)

PB2540: HEPATIC SAFETY PROFILE OF DEFERASIROX IN CHILDREN WITH BETA THALASSEMIA MAJOR IN OMAN
por: Almadhani, Shaimaa, et al.
Publicado: (2023)

PB2539: GEOGRAPHICAL PREVALENCE OF THALASSEMIA GENE MUTATION IN THE PHILIPPINES
por: Velasco, Manuel Jr, et al.
Publicado: (2023)

PB2544: GAUCHER-LIKE CELLS IN THALASSEMIA INTERMEDIA: IS IT A CHALLENGE?
por: Komninaka, Veroniki, et al.
Publicado: (2023)

PB2238: ΒETA-THALASSEMIA INTERMEDIA: INTERACTION OF ΑLPHA-GLOBIN GENE TRIPLICATION WITH ΒETA-THALASSEMIA HETEROZYGOUS IN SPAIN
por: Ropero, P., et al.
Publicado: (2022)

PB2543: CIRCULATING MICROVESICLES AS POTENTIAL CELLULAR BIOMARKERS FOR THROMBOTIC RISKS IN BETA THALASSEMIA
por: Chebbi, Mariem, et al.
Publicado: (2023)

PB2029: ACQUIRED ALPHA THALASSEMIA IN ASSOCIATION WITH MYELODYSPLASTIC SYNDROME- A CASE REPORT
por: Balasubramanian, Priyavadhana, et al.
Publicado: (2023)

PB2533: FREQUENCY, PATTERN, AND CLINICAL CORRELATES OF RENAL IRON ACCUMULATION IN THALASSEMIA MAJOR
por: Meloni, Antonella, et al.
Publicado: (2023)

PB2538: FEASIBILITY AND SAFETY OF POWERPICC SOLO INSERTION THE SAPHENOUS VEIN IN CHILDREN WITH THALASSEMIA
por: Ren, Qin, et al.
Publicado: (2023)

PB2339: PROJECTED LIFETIME ECONOMIC BURDEN OF TRANSFUSION DEPENDENT BETA-THALASSEMIA IN THE UNITED STATES
por: Udeze, C., et al.
Publicado: (2022)

PB2234: HEALTH LITERACY LEVEL ASSOCIATED WITH THALASSEMIA AMONG TUNISIAN’S YOUTH AND PROSPECTS FOR PRIMARY PREVENTION
por: Maaoui, F., et al.
Publicado: (2022)

PB2519: THE EFFECT OF PREVENTIVE HEALTH PROGRAM ON KNOWLEDGE AND SCREENING OF SICKLE CELL DISEASE AMONG HIGH SCHOOL AGED GROUP – THE SAUDI ARABIA EXPERIENCE
por: Ezzat, Hatoon
Publicado: (2023)

PB2233: SYSTEMATIC LITERATURE REVIEW OF HEALTH-RELATED QUALITY OF LIFE BURDEN IN PATIENTS ACROSS THE SPECTRUM OF THALASSEMIA
por: Musallam, K. M., et al.
Publicado: (2022)

PB2239: DOES SIZE MATTER? THREE NEW DELETIONS IN THE HBB GENE CAUSE Β0-THALASSEMIA
por: Ropero, P., et al.
Publicado: (2022)

PB2537: PREDICTORS OF BACTERIAL INFECTION AMONG TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS IN A TERTIARY GOVERNMENT HOSPITAL IN THE PHILIPPINES
por: Baylon, Angelica Kristine, et al.
Publicado: (2023)

PB2090: TREATMENT OUTCOME OF ORBITAL MARGINAL ZONE B CELL LYMPHOMA -- TEN YEARS FOLLOW UP IN A SINGLE INSTITUTION
por: Tan, T.-D., et al.
Publicado: (2022)

PB2434: DONOR CELL INDUCING IMMUNE-TOLERANCE IMPROVED ENGRAFTMENT IN TΑΒ+ CELL DEPLETED HSCT IN PATIENTS WITH THALASSEMIA MAJOR
por: Liao, Jianyun, et al.
Publicado: (2023)

PB2532: VARIABLE HEMATOLOGICAL AND CLINICAL PHENOTYPES IN DOUBLE HETEROZYGOTES OF ΒETA-THALASSEMIA AND TRIPLICATED ΑLPHA-GLOBIN GENES
por: Delaporta, Polyxeni, et al.
Publicado: (2023)

PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW
por: Kattamis, A., et al.
Publicado: (2022)

PB2309: OUTCOMES OF 22 PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: SINGLE INSTITUTE EXPERIENCE
por: Tumyan, Gayane, et al.
Publicado: (2023)

PB2701: SAFETY OF 30 MINUTES INFUSION OF RITUXIMAB BIOSIMILAR. A COHORT STUDY.
por: Palomares, Laida Cuevas, et al.
Publicado: (2023)

PB2218: CHILDHOOD MYELPROLIFERATIVE NEOPLASMS; A SINGLE CENTER EXPERIENCE
por: Ghali, Hasanein, et al.
Publicado: (2023)

PB2235: COMPLETE DELETION OF THE CACCC BOX OF THE HBB GENE PROMOTER: A NEW MECHANISM LEADING TO A SILENT PHENOTYPE OF BETA THALASSEMIA
por: Mondesert, E., et al.
Publicado: (2022)

PB2028: ACQUIRED Α-THALASSEMIA IN A PATIENT WITH HIGH-RISK MYELODYSPLASTIC SYNDROME AND BONE MARROW FIBROSIS: CASE REPORT AND LITERATURE REVIEW
por: Chissan, Sofia, et al.
Publicado: (2023)

PB2179: RETROSPECTIVE ANALYSIS OF THE EFFICACY AND SAFETY OF RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD). A SINGLE-INSTITUTION EXPERIENCE.
por: Muñiz, Ó., et al.
Publicado: (2022)

PB1810: OUTCOME OF ACUTE MYELOID LEUKEMIA RELAPSE AFTER ALLOGENIC STEM CELL TRANSPLANT: A SINGLE INSTITUTION RETROSPECTIVE STUDY
por: Castoldi, C., et al.
Publicado: (2022)

PB1737: OUTCOME OF ACUTE LYMPHOBLASTIC LEUKEMIA IN INFANTS AT THE NATIONAL CANCER INSTITUTE EGYPT: 10 YEARS’ EXPERIENCE
por: Ali, Nesreen, et al.
Publicado: (2023)

PB2317: COINHERITANCE OF COMBINED FACTOR VII AND FACTOR XIII DEFICIENCY IS ASSOCIATED WITH A MILD BLEEDING PHENOTYPE IN PATIENT WITH NON-TRANSFUSION DEPENDENT THALASSEMIA
por: Alshareef, O., et al.
Publicado: (2022)

PB2218: ASSESSMENT OF CYSTATIN C IN PEDIATRIC SICKLE CELL DISEASE AND B-THALASSEMIA AS A MARKER OF SUBCLINICAL CARDIOVASCULAR DYSFUNCTION: A CASE-CONTROL STUDY
por: Beshir, M., et al.
Publicado: (2022)

PB2255: ANTIMICROBIAL SUSCEPTIBILITY TO MICROORGANISMS IN HEMATOLOGICAL MALIGNANCIES; A NEED TO REVIEW INSTITUTIONAL PROTOCOLS
por: ANWAR, N., et al.
Publicado: (2022)

PB2609: 14 YEARS OF EXPERIENCE WITH THROMBOPOIETIN RECEPTOR AGONISTS IN A SINGLE CENTER
por: Garcia-Pallarols, Francesc, et al.
Publicado: (2023)

PB2224: IMPACT OF COVID-19 PANDEMIC ON PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM THE REAL WORLD ASSESSMENT SURVEY FOR SICKLE CELL DISEASE IN SAUDI (ROARS)
por: Ezzat, H., et al.
Publicado: (2022)

PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: Lal, A., et al.
Publicado: (2022)

PB2535: TRIAL IN PROGRESS: A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUSPATERCEPT TO TREAT ANEMIA IN ADULTS WITH ALPHA-THALASSEMIA
por: Viprakasit, Vip, et al.
Publicado: (2023)

PB2630: ASSESSEMENT OF THE MANAGEMENT OF ITP IN ADULTS IN AN INTERNAL MEDICINE DEPARTMENT IN ALGERIA
por: Imene, Semoud, et al.
Publicado: (2023)

PB1835: THE ISTH-DIC SCORE PREDICTS 30-DAYS OUTCOME IN NON-M3 ACUTE MYELOID LEUKEMIA PATIENTS
por: Paterno, G., et al.
Publicado: (2022)

PB1756: EPIDEMIOLOGY OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A RETROSPECTIVE 6-YEAR SINGLE CENTRE EXPERIENCE
por: Kociaj, Jora, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vo1pd0c5rurqq7k4vdlj65bh5l